01—Abstract
Summary
Summary of the 10-K filed February 16, 2024. Cited figures are marked; the original filing is the authoritative source.
HCA Healthcare's FY2023 10-K shows a company with strong top-line growth but lower bottom-line earnings.
Revenue rose 7.9% to $64.968 billiona, driven by a 4.9% increase in equivalent admissions and a 2.8% increase in revenue per equivalent admission. Net income attributable to HCA fell 7.1% to $5.242 billion, or $18.97 per diluted share, versus $19.15 in 2022. The decline reflects the absence of 2022's $1.301 billion in facility sale gains, along with higher salaries, other operating expenses (up to 19.8% of revenue from 18.5%), and interest expense ($1.938 billion, up from $1.741 billion).
Operating cash flow improved to $9.431 billionb, and the company returned capital through $3.811 billion in buybacks and $661 million in dividends. Balance sheet leverage remains the central investor consideration. Total debt was $39.593 billion at year-end 2023, with the average effective interest rate on long-term debt rising to 5.0% from 4.7%.
Management plans capital expenditures of $5.1 to $5.3 billionc in 2024, and a new $6 billion buyback authorization was approved in January 2024 alongside a raised quarterly dividend of $0.66. Key risks include heavy concentration in Florida and Texas (51% of revenue), reliance on Medicare and Medicaid (44.1% of revenue), exposure to a July 2023 cybersecurity incident affecting about 11 million patients, and ongoing staffing pressures and regulatory uncertainty around Medicaid supplemental payments.
Overall, HCA combined solid volume growth and pricing with rising costs and interest burden. Investors are weighing sustained cash generation and shareholder returns against a large debt load, reimbursement exposure, and margin pressure from labor and operating expenses.
02—Key points
Key Highlights
- Revenue grew 7.9% to $64.968 billion in 2023, with equivalent admissions up 4.9% and revenue per equivalent admission up 2.8%.
- Net income attributable to HCA fell 7.1% to $5.242 billion ($18.97 per diluted share), mainly because 2022 included $1.301 billion in gains on facility sales.
- Operating cash flow rose to $9.431 billion from $8.522 billion, aided by a $695 million working capital improvement.
- Total debt reached $39.593 billion, and interest expense rose 11% to $1.938 billion as the average effective interest rate increased to 5.0%.
- Capital returns totaled $4.5 billion in 2023 ($3.811 billion in buybacks plus $661 million in dividends); a new $6 billion buyback was authorized in January 2024 and the quarterly dividend was raised to $0.66.
- Operations are concentrated in Florida and Texas (96 of 186 hospitals, 51% of revenue), and Medicare plus Medicaid represent 44.1% of revenue.
- A July 2023 security incident affected about 11 million patients; the company reports no material losses to date but flags ongoing cybersecurity risk.
03—One dollar
04—Financials
Financial Highlights
Figures from 10-KFY2023filed February 16, 2024Financial Statements
FY2023 against FY2022
| Line item | FY2023FY2022 | Change |
|---|---|---|
| Revenue | $64.97B$60.23B | +7.9% |
| Operating Expenses | $57.26B$51.65B | +10.9% |
| Interest Expense | $1.94B$1.74B | +11.3% |
| Net Income | $5.24B$5.64B | −7.1% |
| EPS (Basic) | $19.25$19.43 | −0.9% |
| EPS (Diluted) | $18.97$19.15 | −0.9% |
| Shares Outstanding (Basic) | 272.40M290.35M | −6.2% |
| Shares Outstanding (Diluted) | 276.41M294.67M | −6.2% |
05—Questions
Frequently Asked Questions
Why did net income decline in 2023 even though revenue grew nearly 8%?
The 2022 results included a $1.301 billion pretax gain on facility and investment sales, which did not recur in 2023. Operating costs also grew faster than revenue: other operating expenses rose to 19.8% of revenue from 18.5%, and interest expense increased by $197 million. Salaries and benefits, however, fell slightly as a share of revenue, to 45.4% from 46.0%.
How leveraged is HCA, and what are the main debt risks?
Total debt was $39.593 billion at December 31, 2023, up from $38.084 billion. About $36.4 billion carries fixed rates, while $3.2 billion is variable, so a 1% rate increase would reduce pretax earnings by roughly $32 million annually. Debt maturities step up in 2025 through 2027, and the company has $6.1 billion of available credit facilities. Covenants limit dividends, buybacks, and asset sales, and the senior secured credit facilities are secured by a significant portion of company assets.
How dependent is HCA on government payers and specific states?
Medicare and Medicaid together produced 44.1% of 2023 revenue, and managed Medicare and managed Medicaid add further exposure. Florida and Texas generated 51% of revenue and 58% of admissions. Changes to Medicaid supplemental payment programs, state directed payments, and the Medicare DSH formula could materially affect results, and management said it could not estimate the impact of pending supplemental payment program reviews.
What are the main capital allocation priorities?
Planned 2024 capital expenditures are $5.1 to $5.3 billion, up from $4.744 billion in 2023, and projects under construction need about $4.1 billion more over five years. In 2023 HCA repurchased 14.465 million shares for $3.811 billion and paid $661 million in dividends, and it authorized a new $6 billion buyback in January 2024. Management believes operating cash flow and credit facilities will be sufficient for the foreseeable future.
What cybersecurity and legal exposures should investors monitor?
In July 2023 an unauthorized party accessed an external storage location used for email formatting, affecting about 11 million patients. The company reports that no cyber incident has yet caused material losses, but it expects threats to increase. Additional exposures include a qui tam lawsuit in Texas tied to the Medicaid waiver program (Harris County) and an environmental investigation by four California district attorneys. Professional liability reserves stand at $2.089 billion, and a 2.5% change in claim severity could move reserves by about $126 to $137 million.
06—Continue